Inquiry and Endometrial-Online computer program: 27 years of clinical registry for endometrial cancer at the University Medical Centre Maribor

Objective: Clinical registries are designed to collect quality data generated during diagnosis and cancer treatment, post-treatment monitoring, and survival and to enhance patient treatment. Evaluation of registry data allows an improvement of patient care and a comparison between healthcare providers. Our goal is to present a computer-based endometrial cancer registry that could serve as a model for those planning to develop a similar registries. Methods: Comprehensive forms for monitoring patients with endometrial cancer (EC) were introduced at the Department of Gynaecological and Breast Oncology, Maribor General Hospital in 1994. Following the clinical development in treatment approaches to EC. This form has been revised several times. The amendments were based on our experience and new approaches to treatment. The form of Endometrial-Online computer program that we present and is currently in use, was designed in 2014. Results: In the last 27 years, we have collected data on EC patients treated at our institution. The Endometrial-Online computer program enables collection, processing, and analysis of 139 different data, that include patient’s general data, history, diagnostic procedures, histopathological examination results, treatment methods, and post-treatment follow-ups in a rapid and reliable way. Conclusions: The purpose of the Endometrial-Online Registry is the collection of data on cancer patients with the intention of improving diagnosis and treatment. It enables improved day-to-day healthcare service, and comparison of our treatment outcomes with national and international standards. Limitations of such clinical registries can be in an incomplete or incorrect data entry as a consequence of several healthcare professionals taking part in diagnostic work up, treatment and post-treatment follow-up of endometrial cancer patients.

Clinical registry; Computer program; Endometrial cancer

[1] Dos Santos Silva I. Cancer Epidemiology: principles and methods. World Health Organization. International Agency for research on cancer: Lyon, France. 1999.

[2] Oncology Institute. Cancer Registry of Republic of Slovenia and Other Registries. 2022. Available at: https://www.onko-i.si/eng/crs/(Accessed: 29 January 2022).

[3] Hočevar M. Klinični registri v onkologiji. Onkologija. 2011; 15: 14–17.

[4] Takač I, Ferletič M, Arko D, Gorišek B. Follow-up computer program for patients with ovarian malignancy. Računalniški program za spremljanje bolnic z rakom jajčnikov. In Bigec M, Lavrenčič D, Kokol P (eds.) Zbornik referatov II del. Proceedings part II (pp. 43–46). IMS. 1996.

[5] Takač I, Gorišek B. User friendly inquiry and computer program for following patients with ovarian malignancy. Archives of Gynecology and Obstetrics. 1999; 263: 60–68.

[6] Arko D, Takac I. Inquiry and computer program Onko-Online: 25 years of clinical registry for breast cancer at the University Medical Centre Maribor. Radiology and Oncology. 2019; 53: 348–356.

[7] Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2014. 2017. Available at: https://seer.cancer.gov/csr/1975_2014/ (Accessed: 29 January 2022).

[8] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. A Cancer Journal for Clinicians. 2021; 71: 209–249.

[9] Zadnik V, Žagar T. SLORA: Slovenija in rak. Epidemiologija in register raka. Onkološki inštitut Ljubljana. 2021. Available at: www.slora.si (Accessed: 1 November 2021).

[10] Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: an umbrella review of the literature. International Journal of Cancer. 2019; 145: 1719–1730.

[11] Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: a Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention. 2010; 19: 3119–3130.

[12] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569–578.

[13] Haoula Z, Salman M, Atiomo W. Evaluating the association between en-dometrial cancer and polycystic ovary syndrome. Human Reproduction. 2012; 27: 1327–1331.

[14] McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. the Iowa Women’s Health Study. American Journal of Epidemiology. 1996; 143: 1195–1202.

[15] Kitson SJ, Evans DG, Crosbie EJ. Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. Cancer Prevention Research. 2017; 10: 1–13.

[16] Fleming CA, Heneghan HM, O’Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. The British Journal of Surgery. 2018; 105: 1098–1106.

[17] MacKintosh ML, Crosbie EJ. Prevention Strategies in Endometrial Carcinoma. Current Oncology Reports. 2018; 20: 101.

[18] Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT, Ruan ZX, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. International Journal of Cancer. 2006; 119: 2142–2147.

[19] Allen N, Peto R, Beral V, Kan S, Reeves G, Sweetland S, et al. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. The Lancet Oncology. 2015; 16: 1061–1070.

[20] Weiderpass E, Adami H-, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of Endometrial Cancer Following Estrogen Replacement with and without Progestins. JNCI Journal of the National Cancer Institute. 1999; 91: 1131–1137.

[21] Rodriguez GC, Rimel B, Watkin W, Turbov JM, Barry C, Du H, et al. Progestin treatment induces apoptosis and modulates transforming growth factor-beta in the uterine endometrium. Cancer Epidemiology Biomarkers and Prevention. 2008; 17: 578–584.

[22] Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013; 78: 782–785.

[23] Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, et al. Breastfeeding and Endometrial Cancer Risk: an Analysis from the Epidemiology of Endometrial Cancer Consortium. Obstetrics and Gynecology. 2017; 129: 1059–1067.

[24] Zhan B, Liu X, Li F, Zhang D. Breastfeeding and the incidence of endometrial cancer: a meta-analysis. Oncotarget. 2015; 6: 38398–38409.

[25] Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. American journal of epidemiology. 2012; 176: 269–278.

[26] Royal College of Obstetrics and Gynaecology, Guideline. Long-term consequences of polycystic ovary syndrome. 2014. Available at: https: //www.rcog.org.uk/media/qmtlp2b0/gtg_33.pdf (Accessed: 29 January 2022).

[27] Neacşu A, Marcu ML, Stănică CD, Brăila AD, Pacu I, Ioan RG, et al. Clinical and morphological correlations in early diagnosis of endometrial cancer. Romanian Journal of Morphology and Embryology. 2018; 59: 527–531.

[28] Zuber TJ. Endometrial biopsy. American Family Physician. 2001; 63: 1131–1141.

[29] Develioglu OH, Bilgin T, Yalcin OT, Ozalp S. Transvaginal ultrasonog-raphy and uterine artery Doppler in diagnosing endometrial pathologies and carcinoma in postmenopausal bleeding. Archives of Gynecology and Obstetrics. 2003; 268: 175–180.

[30] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[31] Šegedin B, Merlo S, Smrkolj S, Bebar S, Blatnik A, Cerar O, et al. Priporočila za obravnavo bolnic z rakom materničnega telesa. Onkologija. 2018; 22: 96–114.

[32] WHO Classification of Tumours Editorial Board. Female Genital Tumours. WHO Classification of Tumours (pp. 632). 5th edn. World Health Organization: Switzerland. 2020.

[33] Masood M, Singh N. Endometrial carcinoma: changes to classification (WHO 2020). Diagnostic Histopathology. 2021; 27: 493–499.

[34] Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. International Journal of Gynecological Pathology. 2007; 26: 115–123.

[35] Bellaminutti S, Bonollo M, Gasparri ML, Clivio L, Migliora P, Mazzucchelli L, et al. Sentinel lymph node intraoperative analysis in endometrial cancer. Journal of Cancer Research and Clinical Oncology. 2020; 146: 3199–3205.

[36] Jeppesen MM, Mogensen O, Hansen DG, Bergholdt SH, Jensen PT. How do we Follow up Patients with Endometrial Cancer? Current Oncology Reports. 2019; 21: 57.

[37] Lu KH, Broaddus RR. Endometrial Cancer. New England Journal of Medicine. 2020; 383: 2053–2064.

[38] Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76: 151–156.

[39] Raffone A, Travaglino A, Raimondo D, Boccellino MP, Maletta M, Borghese G, et al. Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma. Gynecologic Oncology. 2021; 161: 621–628.

[40] Habiba M, Pluchino N, Petignat P, Bianchi P, Brosens IA, Benagiano G. Adenomyosis and Endometrial Cancer: Literature Review. Gynecologic and Obstetric Investigation. 2018; 83: 313–328.